Page 113 - E-Klipping EUA Vaksin Comirnaty Produksi Pfizer and BioNTech

This vaccine differs from the COVID-19 vaccine of Sinovac, China, which is being
tested in phase III clinical trials.

The difference lies in the fact that Sinovac uses a single virus that is multiplied in the
laboratory. The virus is isolated, and it is an inactivated vaccine to make it safe for
human administration. Hence, it is a whole virus vaccine.

In the meantime, the Red and White vaccine is being developed by employing a
recombinant method, wherein instead of the whole virus only certain parts of it are
deemed important that will then be multiplied and used as antigens.

The animal testing trials of the Red and White vaccine is expected to be completed in
2020. If it is effective, the seed vaccine will be submitted to Bio Farma for preclinical
and clinical trials. Related news: 1,020 volunteers to partake in Chinese vaccine trials
in Indonesia